JP2024544075A - ブルーリ潰瘍におけるマイコバクテリウム・ウルセランスの局所治療のための製剤及び方法 - Google Patents

ブルーリ潰瘍におけるマイコバクテリウム・ウルセランスの局所治療のための製剤及び方法 Download PDF

Info

Publication number
JP2024544075A
JP2024544075A JP2024532467A JP2024532467A JP2024544075A JP 2024544075 A JP2024544075 A JP 2024544075A JP 2024532467 A JP2024532467 A JP 2024532467A JP 2024532467 A JP2024532467 A JP 2024532467A JP 2024544075 A JP2024544075 A JP 2024544075A
Authority
JP
Japan
Prior art keywords
clofazimine
pharmaceutical composition
topical pharmaceutical
composition according
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544075A5 (https=
Inventor
ホフマン、トーマス
バナスチュースキ、ブランドン
Original Assignee
マンカインド コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マンカインド コーポレイション filed Critical マンカインド コーポレイション
Publication of JP2024544075A publication Critical patent/JP2024544075A/ja
Publication of JP2024544075A5 publication Critical patent/JP2024544075A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024532467A 2021-11-30 2022-11-29 ブルーリ潰瘍におけるマイコバクテリウム・ウルセランスの局所治療のための製剤及び方法 Pending JP2024544075A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163284426P 2021-11-30 2021-11-30
US63/284,426 2021-11-30
PCT/US2022/080537 WO2023102363A1 (en) 2021-11-30 2022-11-29 Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers

Publications (2)

Publication Number Publication Date
JP2024544075A true JP2024544075A (ja) 2024-11-27
JP2024544075A5 JP2024544075A5 (https=) 2025-12-05

Family

ID=86613091

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532467A Pending JP2024544075A (ja) 2021-11-30 2022-11-29 ブルーリ潰瘍におけるマイコバクテリウム・ウルセランスの局所治療のための製剤及び方法

Country Status (5)

Country Link
US (1) US20240390366A1 (https=)
JP (1) JP2024544075A (https=)
CN (1) CN118317771A (https=)
AU (1) AU2022399569A1 (https=)
WO (1) WO2023102363A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610198A (en) * 1994-03-18 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases
WO2007085057A1 (en) * 2006-01-25 2007-08-02 The Council Of The Queensland Institute Of Medical Research A medical protocol
US9018216B2 (en) * 2012-07-18 2015-04-28 Vertex Pharmaceuticals Incorporated Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
WO2016179231A1 (en) * 2015-05-04 2016-11-10 Board Of Trustees Of Michigan State University Compositions and methods for inhibiting bacterial growth
WO2019018692A1 (en) * 2017-07-19 2019-01-24 The Regents Of The University Of Colorado, A Body Corporate METHODS OF ASSESSING TREATMENT EFFICIENCY AND / OR TREATMENT DURATION IN MYCOBACTERIAL DISEASES
WO2021184339A1 (en) * 2020-03-20 2021-09-23 Merck Sharp & Dohme Corp. Oxazolidinone compound and methods of use thereof as an antibacterial agent
KR20230004644A (ko) * 2020-04-17 2023-01-06 선전 파마신 컴퍼니 리미티드 약제학적 조성물
CA3177438A1 (en) * 2020-05-01 2021-11-04 Thomas Hofmann Clofazimine composition and method for the treatment or prophylaxis of viral infections

Also Published As

Publication number Publication date
WO2023102363A1 (en) 2023-06-08
CN118317771A (zh) 2024-07-09
AU2022399569A1 (en) 2024-06-06
US20240390366A1 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
JP3240330B2 (ja) コラン酸の塩を含有する医薬調合剤および化粧品調合剤
US20050255048A1 (en) Sprayable formulations for the treatment of acute inflammatory skin conditions
HUE027184T2 (en) Combination of azelastine and cyclesonide
EP1477166A1 (de) Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis
JP2020505469A (ja) 治療用アプレミラスト局所組成物
JP2001504091A (ja) 病原性生物による鼻咽腔のコロニー形成に関連する細菌感染の治療のための薬剤の製造のためのミュピロシンの使用
JP2007505927A (ja) 薬物送達システム
JP2012051892A (ja) マイクロエマルジョンおよび気道疾患を防ぐためのその使用
JP2022512208A5 (https=)
WO2007126865A2 (en) Leukotriene antagonists via nasal drug delivery
JP2007509952A (ja) ロテプレドノールエタボネートおよびトブラマイシンの局所眼科用懸濁液
AU2008331500B2 (en) Intravesical compositions with valrubicin for the treatment of bladder cancer
JP2024544075A (ja) ブルーリ潰瘍におけるマイコバクテリウム・ウルセランスの局所治療のための製剤及び方法
US8263567B2 (en) Treatment of hyperproliferative conditions of body surfaces
HK40111713A (zh) 用於局部治疗布鲁里溃疡中的溃疡分枝杆菌的制剂和方法
US20210038503A1 (en) Compositions and methods for topical treatment of dermal and ocular conditions
US20230149352A1 (en) Uses of apremilast
WO2009007827A2 (en) Novel diclofenac esters and uses thereof
JP2024544075A5 (https=)
JP7512365B2 (ja) 油性外用液
AU2002320964A1 (en) Treatment of hyperproliferative conditions of body surfaces
WO2024159048A1 (en) Treatment of uremic pruritus
WO2005053672A1 (ja) シロミラストまたはその塩を有効成分とする掻痒治療剤
HK40129381A (zh) 慢性瘙痒性皮肤病的治疗
JP2005187458A (ja) シロミラストまたはその塩を有効成分とする掻痒治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251127